N/A N=32 PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
Critical Limb Ischemia · Chronic Limb-Threatening Ischemia
Primary: Amputation-free Survival — 90.6 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,533 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
Respiratory Syncytial Virus Infections
Primary: RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group — 7906.0; 7518.9 Titer
Phase 1 N=55 Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Part 1 - Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide (CO2) Point (VE55) on Day 1 for Oxycodone Combined With Midazolam and Oxycodone Alone. — 21.9; 24.1…
Phase 2 N=92 Magnesium for Peroral Endoscopic Myotomy
Esophageal Spasm
Primary: Esophageal Symptoms Questionnaire Score (ESQ) — 24; 35 score on a scale
Phase 4 N=75 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 62 Participants
Phase 4 N=50 Low Dose Ketamine for Blunt Thoracic Trauma
Blunt Injury of Thorax · Multiple Rib Fractures, Involving Three Ribs
Primary: Milligrams of Morphine Equivalents (MME) Administered — 84.9; 81.7 Morphine Milligam Equivalents (MME)
Phase 2 N=26 Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
Glioblastoma Multiforme
Primary: 6-month Progression-free Survival (PFS) — 1 Participants
Phase 2 N=52 Nivolumab Plus Ipilimumab in Thyroid Cancer
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Phase 2 N=8 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Liver Metastases · Lung Metastases · Recurrent Melanoma
Primary: Rate of Progression-free Survival by mWHO Criteria — 0.75 months
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
N/A N=129 Ca:Mg Ratio and Cognitive Function
Cognitive Function
Primary: Overall Score Changes From Baseline by Magnesium Treatment vs. Placebo — 1.1; 0.6 score on a scale — p=0.20
N/A N=35 Brief Family-involved Treatment for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Form-90 Timeline Followback Interview — .78; .64 proportion of days abstinent
N/A N=57 An Intraoperative Guidance Platform for Radio Frequency Ablation
Hepatocellular Carcinoma
Primary: Rate of Technical Success of Tumor Ablation — 68; 0 tumors
Phase 2 N=23 Ghrelin (OXE--103) for Acute Concussion Management
Concussion, Brain · Traumatic Brain Injury
Primary: Symptom Management - Post Concussion Symptom Scale — 44; 71; 39; 51 score on a scale
N/A N=1,215 Comparison of Text and Pictorial Waterpipe Tobacco Warnings Among Young Adults
Waterpipe Tobacco Smoking
Primary: Behavioral Intentions — 1.83; 1.72; 2.21 score on a scale